Physician profile
Michael B Turner
NPI 1598851404
$3,698.73
in general payments reported to CMS, 2019-2025
27 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $87.33 · 2021: $53.48 · 2022: $437 · 2023: $423 · 2024: $973 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.71 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $463.77 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $311.03 | 2019-2025 | |
| Janssen Biotech, INC. | $293.27 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $238.84 | 2019-2025 | Ilumya, Winlevi |
| Ucb, INC. | $202.06 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $191.91 | 2019-2025 | |
| Organon LLC | $190.80 | 2025 | Vtama |
| Amgen INC. | $161.16 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $140.41 | 2019-2025 | Taltz, Ebglyss |
| Incyte Corporation | $127.59 | 2021-2022 | |
| Leo Pharma INC. | $127.12 | 2024-2025 | Adbry, Anzupgo |
| Pfizer INC. | $100.60 | 2019-2025 | |
| Galderma Laboratories, L.P. | $72.51 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $68.32 | 2023-2024 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $53.36 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.96 | 2022-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.19 | 2024-2025 | Siliq |
| Blueprint Medicines Corporation | $41.58 | 2024 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $22.43 | 2024 | Sotyktu |
| Kyowa Kirin, INC. | $20.87 | 2025 | |
| Celgene Corporation | $16.88 | 2019 | |
| Mayne Pharma Commercial LLC | $16.18 | 2019 | |
| Botanix Sb INC | $15.71 | 2025 | Sofdra |
| Allergan, INC. | $15.12 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $13.68 | 2020 | |
| Prugen, INC. Pharmaceuticals | $10.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.